The heterocytotoxicity of human serum. I. Activation of the alternative complement pathway by heterologous target cells.
D000818:Animals; D000906:Antibodies; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D002460:Cell Line; D003176:Complement C3; D003165:Complement System Proteins; D003601:Cytotoxicity Tests, Immunologic; D004912:Erythrocytes / Q000276:immunology; D006801:Humans; D007104:Immune Adherence Reaction; D066298:In Vitro Techniques; D008214:Lymphocytes / Q000276:immunology*; D012515:Mast-Cell Sarcoma / Q000276:immunology / Q000378:metabolism; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000378:metabolism; D011414:Properdin / Q000276:immunology; D013154:Spleen / Q000276:immunology; D013945:Thymoma / Q000276:immunology / Q000378:metabolism; D013950:Thymus Gland / Q000276:immunology
D000906:Antibodies; D003176:Complement C3; D011414:Properdin; D003165:Complement System Proteins